Skip to main content

Table 4 Treatment of study patients during hospitalization

From: Factors affecting in-hospital mortality of non-tuberculous mycobacterial pulmonary disease

  Total (%) Death (%) P-value
n = 16,192 n = 3166
Medications prescribed during hospitalization
 No use of NTM drugsa 7215 (44.6) 1504 (47.5) < 0.001
 Erythromycin only 526 (3.2) 61 (1.9) < 0.001
 RIF, EMB, CLR 1676 (10.4) 232 (7.3) < 0.001
 RIF, EMB, CLR, +FQ and/or AG 778 (4.8) 188 (5.9) 0.001
 Corticosteroidsb 3383 (20.9) 1069 (33.8) < 0.001
Treatment procedure
 Bronchial artery embolization 250 (1.5) 22 (0.7) < 0.001
 Mechanical ventilation 1518 (9.4) 957 (30.2) < 0.001
  1. aNTM drugs include the followings: rifampicin and rifabutin; ethambutol; isoniazid; macrolides, including clarithromycin and azithromycin; aminoglycosides, including streptomycin, kanamycin and amikacin; fluoroquinolones, including levofloxacin, moxifloxacin and sitafloxacin; and imipenem/cilastatin
  2. bCorticosteroids include those administered both orally and intravenously
  3. Abbreviations: AG aminoglycoside, CLR clarithromycin, EMB ethambutol, FQ fluoroquinolone, NTM non-tuberculous mycobacterial pulmonary disease, RIF rifampicin